Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, posted on LinkedIn:
“An unforgettable night at ASCO25 with SAGA Diagnostics.
Last evening, I had the privilege of presenting on the power of high-sensitivity ctDNA detection using our Pathlight MRD platform and engaging in a dynamic expert panel discussion alongside thought leaders in the space.
Together, we explored the future of molecular residual disease (MRD) detection and its clinical impact on personalized cancer care. The insightful dialogue and passionate exchange of ideas reaffirmed our shared commitment to advancing precision oncology.
A special thanks to everyone who joined us — the energy, questions, and connections made the night truly meaningful.”
More posts featuring ASCO25.